ArticleJNCI cancer spectrum2026
Comparing chemotherapy-induced nausea and vomiting between young adult vs non-young adult cancer patients.
Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Chemotherapy-induced nausea and vomiting are among the most distressing side effects of cancer therapy. Younger age is a risk factor for chemotherapy-induced nausea and vomiting, and cancer incidence is rising among young adults ages 18-39 years. However, the comparative burden of chemotherapy-induced nausea and vomiting in young adults vs non-young adults remains insufficiently understood. This study compared acute and delayed chemotherapy-induced nausea and vomiting between young adults and non-young adults (ie, ages 40 years and older) after the first infusion of moderately or highly emetogenic chemotherapy. Of 1609 participants, 159 (10%) were young adults. Rates of guideline-consistent antiemetic prophylactic care were similar between groups (65% young adults, 71% non-young adults; P = .11). Despite this, acute nausea was more prevalent (69% vs 40%; P < .001) and severe (mean [SD] = 3.9 [2.6] vs mean = 3.0 [2.3] on 0-10 scale; P < .001) among young adults vs non-young adults. Similarly, delayed nausea was more prevalent (85% vs 69%; P < .001) and severe (mean = 4.5 [2.4] vs mean = 3.7 [2.5]; P < .001) among young adults. Findings may inform clinical approaches to managing chemotherapy-induced nausea and vomiting among young adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.